The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications

NCT04435015 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No funding

Conditions

Coagulopathy
Cardiovascular Complication
COVID-19

Interventions

DRUG: Camostat Mesylate
DRUG: Microcrystalline Cellulose, NF

Sponsor

Yale University

Collaborators

[object Object]